The Regai Dzive Shiri Project: a cluster randomised controlled trial to determine the effectiveness of a multi-component community-based HIV prevention intervention for rural youth in Zimbabwe – study design and baseline results

<p>Baseline results for the Regai Dzive Shiri trial published in Tropical Medicine and International Health in 2008 describing trial methods</p

Sub-group analyses.

<p>Sub-group analyses.</p

Characteristics of included studies.

a<p>Data from study area, or Joint United Nations Programme on HIV/AIDS national data (adult prevalence) if shown in italics.</p>b<p>Eligible if <13 y and mother HIV-positive, mother HIV status unknown, or mother dead.</p>c<p>35,815/137,268 encountered in the area.</p>d<p>Stated only as following national guidelines for testing.</p>e<p>Excluded non-English and non-Lugandan speakers.</p>f<p>Eligible if mother deceased or HIV-positive.</p>g<p>Study done in period before antiretrovirals were available.</p><p>ELISA, enzyme-linked immunosorbent assay; FP, finger prick; RDT, rapid diagnostic test; VCT, voluntary counselling and testing.</p

Flow diagram of study selection process.

<p>Flow diagram of study selection process.</p

Proportion achieving knowledge of HIV status overall.

<p>Proportion achieving knowledge of HIV status overall.</p

Proportion accepting HBT.

<p>Proportion accepting HBT.</p

Assessment of study rigour.

a<p>Where no information is available “not specified” is indicated for these variables, as we considered it possible that these activities were done but not reported in the paper.</p>b<p>Some studies offered testing but results were not promised, e.g., results available only if client sought the result separately; some studies were entirely blinded, e.g., where testing was done for anonymous population HIV prevalence estimation.</p

The cascade of care following community-based detection of HIV in sub-Saharan Africa – A systematic review with 90-90-90 targets in sight - Fig 2

<p><b>a-d: Forest plots showing</b>: </p><p></p><p></p><p><b>Proportions linked-to-care (LTC) by HTS approach (a)</b></p><p></p><p></p><p><b>Proportions LTC by PLWH sub-groups (b)</b></p><p></p><p></p><p><b>Proportions LTC by when CD4-count result was available (c)</b></p><p></p><p></p><p><b>Proportions initiating ART (among those eligible) by HTS approach (d)</b></p><p></p><p></p><p></p> <p><b>Proportions linked-to-care (LTC) by HTS approach (a)</b></p> <p><b>Proportions LTC by PLWH sub-groups (b)</b></p> <p><b>Proportions LTC by when CD4-count result was available (c)</b></p> <p><b>Proportions initiating ART (among those eligible) by HTS approach (d)</b></p

Key characteristics of included studies.

<p>Key characteristics of included studies.</p

Markers of study quality.

<p>Markers of study quality.</p